Company intelligence / Profile preview
Hinge Bio, Inc.
Burlingame, California, United Stateshingebio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead candidate HB2198 has shown pre-clinical in vivo results with deeper and more rapid B cell depletion than other antibody-based therapies. The goal is immune system reset via rapid and deep B cell depletion in both peripheral blood and lymphoid tissues. Clinical trials are planned for Lupus patients starting in or after mid/late 2025. No clinical data yet available.
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- Multivalent antibody-based therapeutics (GEM-DIMER™ platform)Multispecific antibodiesCooperative binding biologics
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Not specified; company notes interest from pharmaceutical partners [2].
Beyond the preview
Go deeper on Hinge Bio, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hinge Bio, Inc..